Activation of the alternative complement pathway due to resistance of zymosan-bound.
- 1 April 1977
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 74 (4), 1683-1687
- https://doi.org/10.1073/pnas.74.4.1683
Abstract
The surface of zymosan (Zy), by affording a protected microenvironment for C3b [b fragment of complement component 3] and the amplification convertase stabilized by properdin (P)C3bBb [b fragment of Factor B], shifts the alternative complement pathway from slow fluid phase turnover to the amplification phase of its expression. This mode of activation is in contradistinction to that of the classical pathway, which follows conversion of a proenzyme, C1, to its active form, C.hivin.1. Under conditions in which the control proteins, C3b inactivator (C3bINA) and .beta.1H, completely inactivated C3b on the sheep erythrocyte [E] intermediate, EA[antibody]C4b3b, the activity of C3b bound to Zy, ZyC3b, was diminished by only 1/3. When ZyC3b was converted to ZyC3bBbP, there was an additional point of deregulation in that the convertase was resistant to .beta.1H-mediated decay-dissociation while PC3bBb on the sheep erythrocyte exhibited the usual susceptibility to .beta.1H. That Zy alone could promote rapid C3 cleavage by the alternative pathway through assembly and protection of the amplification convertase on its surface was demonstrated with a mixture of alternative pathway proteins, C3, B, .hivin.D, P, C3bINA and .beta.1H, that were each purified to homogeneity. Interaction of these proteins at 1/10 their relative serum concentrations with Zy permitted low-grade inactivation of C3 and B to advance to the level of amplification after a 15 min lag period. Because the reaction of the purified proteins proceeded spontaneously when either regulatory protein was deleted, the effect of Zy was attributed to deregulation rather than to conversion of one of the proteins to a specific initiating state. The alternative pathway, through the normal presence of .hivin.D, interacts with a microbial surface, such as Zy, to amplify deposition of C3b by circumvention of endogenous regulatory mechanisms, thereby augmenting host defense.This publication has 31 references indexed in Scilit:
- Modulation of the alternative complement pathways by beta 1 H globulin.The Journal of Experimental Medicine, 1976
- Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function.The Journal of Experimental Medicine, 1976
- Control of the amplification convertase of complement by the plasma protein beta1H.Proceedings of the National Academy of Sciences, 1976
- Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase.The Journal of Experimental Medicine, 1975
- THE MEMBRANE ATTACK MECHANISM OF COMPLEMENTThe Journal of Experimental Medicine, 1973
- C3 PROACTIVATOR CONVERTASE AND ITS MODE OF ACTIONThe Journal of Experimental Medicine, 1972
- THE C3-ACTIVATOR SYSTEM: AN ALTERNATE PATHWAY OF COMPLEMENT ACTIVATIONThe Journal of Experimental Medicine, 1971
- C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b.1971
- CHROMATOGRAPHIC RESOLUTION OF THE FIRST COMPONENT OF HUMAN COMPLEMENT INTO THREE ACTIVITIESThe Journal of Experimental Medicine, 1963
- The Properdin System and Immunity: I. Demonstration and Isolation of a New Serum Protein, Properdin, and Its Role in Immune PhenomenaScience, 1954